XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Operating activities    
Net loss $ (12,709,625) $ (12,171,623)
Adjustments to reconcile net loss to net cash used in operating activities:    
Impairment loss 34,169 0
Depreciation 348,748 372,828
Stock-based compensation expense 820,969 615,226
Change in fair value of derivative financial instruments—warrants 186,072 (27,359)
Release of clinical trial funding commitment 868,093 509,034
Changes in operating assets and liabilities:    
Other assets 1,806 (68,145)
Accounts receivable and unbilled receivable (886) 15,717
Prepaid expenses (623,902) 277,876
Operating lease right-of-use assets 240,086 224,400
Accounts payable and accrued expenses 318,991 837,551
Operating lease liabilities (635,630) (576,141)
Other liabilities (39,916) 0
Net cash used in operating activities (11,191,025) (9,990,636)
Investing activities:    
Capital expenditures (153,784) (67,622)
Net cash used in investing activities (153,784) (67,622)
Financing activities:    
Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $633,807 and $97,260, respectively 18,278,429 4,386,321
Costs related to the clinical trial funding commitment (7,500) (40,000)
Proceeds from exercise of options 6,832 0
Proceeds from exercise of warrants 18,972,188 3,291,010
Borrowings under note payable 305,000 0
Net cash provided by financing activities 37,554,949 7,637,331
Net change in cash and cash equivalents 26,210,140 (2,420,927)
Cash and cash equivalents—Beginning of period 10,195,292 11,453,133
Cash and cash equivalents—End of period 36,405,432 9,032,206
Supplementary disclosure of cash flow activity:    
Cash paid for taxes 800 800
Supplemental disclosure of non-cash investing and financing activities:    
Preferred stock dividend payable on Series A Convertible Preferred Stock 18,180 18,180
Series C Convertible Preferred Stock    
Supplemental disclosure of non-cash investing and financing activities:    
Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance 0 268,269
Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment 0 1,675,000
Common stock issued upon conversion of convertible preferred stock 0 33
Series D Convertible Preferred Stock    
Supplemental disclosure of non-cash investing and financing activities:    
Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance 601,767 0
Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment 2,300,000 0
Common stock issued upon conversion of convertible preferred stock 155 0
Series E Convertible Preferred Stock    
Supplemental disclosure of non-cash investing and financing activities:    
Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance $ 2,664,717 $ 0